The complete beginner's guide to peptide therapy in Australia

Peptides are short chains of amino acids — the building blocks of proteins — that act as biological signalling molecules in the body. Your body produces thousands of peptides naturally: hormones like insulin and glucagon are peptides, as are many neurotransmitters and growth factors. Peptide therapy involves using synthetic versions of these naturally occurring compounds to augment or restore specific biological processes — stimulating growth hormone release, accelerating tissue repair, regulating appetite, or supporting cognitive function. Unlike synthetic drugs, which are typically small molecules that force biological responses, therapeutic peptides work with your body's existing signalling pathways by mimicking or modulating the body's own communications system. This is why they generally have more targeted effects and fewer systemic side effects than traditional pharmaceuticals — though they are not without risks and appropriate medical supervision remains essential.

Every peptide works by binding to specific receptors on cell surfaces. When a peptide binds to its receptor, it triggers a signalling cascade inside the cell — a sequence of molecular events that ultimately changes cell behaviour. Semaglutide, for example, binds to GLP-1 receptors in the gut, pancreas, and brain, triggering insulin release, slowing gastric emptying, and suppressing appetite signals. BPC-157 binds to growth hormone receptors and promotes the production of growth factors like VEGF, which drives angiogenesis (formation of new blood vessels) and tissue repair. Ipamorelin binds to the ghrelin receptor on pituitary cells, triggering growth hormone release. The specificity of this receptor-binding mechanism is what allows peptides to have highly targeted effects — and it is also why different peptides are used for different goals. There is no universal peptide that does everything; each is designed around a specific receptor interaction and a specific therapeutic outcome.

Peptide therapy in Australia operates within a specific regulatory framework administered by the Therapeutic Goods Administration (TGA). Most therapeutic peptides are classified as Schedule 4 substances — prescription-only medicines — which means they can only be legally accessed via a valid prescription from an AHPRA-registered medical practitioner. The two primary legal access pathways are: (1) TGA-approved products — semaglutide (Wegovy, Ozempic) and a small number of other peptides have full TGA product approval and are dispensed by registered pharmacies; and (2) the compounding exemption — most peptides (BPC-157, Ipamorelin/CJC-1295, TB-500 and others) are not TGA-approved as standalone products but can be legally prescribed by a registered practitioner and dispensed by a licensed Australian compounding pharmacy as individually prepared medicines. The compounding pathway is the standard route for most peptide therapy in Australia. Attempting to import or purchase peptides without a prescription is illegal and carries real legal and safety risks — unregulated overseas suppliers cannot guarantee purity, potency, or sterility.

The most important decision in beginning peptide therapy is selecting the right protocol for your primary goal. ProtocolHub organises protocols around seven health goals: fat loss, muscle building, recovery, longevity, hormone health, gut health, and cognitive enhancement. Each goal maps to specific peptides with established evidence for that application. If your goal is fat loss, GLP-1 therapy (semaglutide or tirzepatide) has the strongest clinical evidence base — TGA-approved, extensively studied, and accessible through telehealth clinics. If your goal is recovery from injury or surgery, BPC-157 alone or combined with TB-500 is the most established option. If you want to optimise growth hormone and body composition broadly, Ipamorelin/CJC-1295 is the standard starting point. Beginners should start with a single-peptide protocol at the lowest recommended dose before considering stacking multiple peptides — this allows you to isolate effects, monitor tolerance, and build a relationship with your prescribing practitioner before introducing complexity.

Realistic expectations are essential for adherence to any protocol. Peptide therapy is not a fast-acting pharmaceutical intervention — it works by modulating biological processes that operate on weeks-to-months timescales. For GLP-1 protocols, meaningful appetite suppression typically begins in week 1–2, but significant weight loss is usually measurable by week 8–12 at the full therapeutic dose. For GH secretagogues (Ipamorelin/CJC-1295), improved sleep quality is often the first noticeable effect (weeks 1–2), with changes in body composition typically becoming measurable by week 8–12. For recovery peptides like BPC-157, injury-specific improvements (reduced pain, increased range of motion) are often reported within 2–4 weeks for acute injuries. For cognitive peptides, Selank's anxiolytic effects are typically felt within the first few doses; Noopept's cognitive enhancement within the first week; Semax's longer-term neuroplastic effects over 3–6 weeks. In all cases, the protocol must be maintained consistently to accumulate the biological changes that produce results — sporadic or short-course use rarely achieves the outcomes seen in clinical protocols.

Blood work is not optional in responsible peptide therapy — it is the foundation of safe, evidence-based prescribing. Before beginning any peptide protocol, a responsible prescribing practitioner will require baseline blood markers relevant to your specific protocol. For GH secretagogues, this means IGF-1 (to confirm GH axis function and establish a baseline), fasting glucose (GH can affect insulin sensitivity), and basic metabolic panel. For GLP-1 therapy, HbA1c, fasting glucose, and liver function are standard. After 8–12 weeks on protocol, a retest of relevant markers confirms the protocol is producing the desired biological effect and identifies any safety concerns early. This data-driven approach is what separates legitimate peptide therapy from unsupervised self-experimentation. Clinics that prescribe without baseline or follow-up blood work are not practicing responsible medicine — this is a red flag when evaluating providers.

A thorough initial consultation for peptide therapy should take 30–60 minutes and cover your health history, current medications, specific goals, lifestyle factors, and relevant blood work. The prescriber should explain the mechanism of the peptide being recommended, the expected timeline for results, the monitoring plan, and the process for adjusting or discontinuing the protocol. They should also discuss the legal and regulatory framework and ensure you understand that compounded peptides are individually prepared medicines rather than mass-manufactured pharmaceuticals. Red flags to watch for: prescribers who recommend complex multi-peptide stacks in the first consultation without baseline blood work; clinics that promise specific outcome guarantees; providers who do not follow up or monitor your progress. The Australian telehealth clinics listed in ProtocolHub's comparison tool are independently evaluated against these standards.

Peptides are most effective when the foundational biological substrate is in place. Every peptide protocol should be built on a supplement foundation that addresses the most common deficiencies affecting the target goal. For fat loss protocols, this means adequate protein intake (to prevent muscle loss during caloric deficit), magnesium glycinate (for sleep quality during GLP-1 adaptation), and omega-3 fatty acids (for inflammation management). For GH protocols, creatine (to maintain muscle performance while GH normalises), vitamin D3/K2 (for hormonal health), and high-quality protein are standard. For recovery protocols, collagen peptides with vitamin C (the cofactor for collagen synthesis) and L-glutamine are the primary supplement supports. ProtocolHub's supplement stack builder tool allows you to build a goal-specific supplement plan alongside your peptide protocol — treating them as an integrated system rather than separate interventions.